Alto Neuroscience(ANRO) - 2023 Q4 - Annual Results

Exhibit 99.1 Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights – Reported positive results from ALTO-100 and ALTO-300 Phase 2a studies demonstrating prospective replication of response prediction using Alto's Precision Psychiatry Platform™ – – Patient enrollment on track across Phase 2b MDD studies for two lead product candidates – – Successful completion of oversubscribed initial public offering; cash position of approximately $210 million as of February 29, 2024 – L ...